High-Stakes Ruling Rewrites Women’s Sports

Four female volleyball players celebrating in a gymnasium

The Supreme Court ruled 6-3 in June 2026 to uphold state bans on transgender athletes in women’s sports, and the science behind the decision is far messier than either side wants to admit.

Story Snapshot

The Supreme Court’s 6-3 ruling upheld state laws banning transgender women from competing in women’s sports.
The Court found the bans do not violate Title IX or the Constitution.
A 2024 meta-analysis of 52 studies found no measurable strength or aerobic advantage in transgender women after hormone therapy.
Separate research shows transgender women may retain higher absolute handgrip strength than cisgender women even after treatment.
The science is genuinely unsettled at elite levels, which makes the legal and policy fight even harder to resolve.

What the Supreme Court Actually Decided

The Court’s majority held that states have the right to set sex-based eligibility rules for women’s sports. The ruling did not create a new federal ban. It cleared the legal path for states that already passed such laws to enforce them without fear of a constitutional challenge. The decision lands in the middle of a decade-long fight over who gets to define fairness in women’s athletics.

Title IX, the 1972 federal law that bans sex-based discrimination in schools, sat at the center of the legal argument. Opponents of the bans argued the law protects transgender students. The Court’s majority disagreed, finding that sex-based eligibility categories are consistent with Title IX’s original purpose of protecting women’s athletic opportunities. That interpretation will now shape policy in every state that chooses to act.

The Science Is Real but Incomplete

A 2024 meta-analysis reviewed 52 studies covering 6,485 participants. It found no measurable difference in upper or lower body strength or aerobic capacity between transgender women and cisgender women after one to three years of hormone therapy. That is a significant finding. It directly challenges the assumption that transgender women always carry a physical advantage into competition after treatment.

But the science does not stop there. The same British Journal of Sports Medicine research that showed no aerobic gap also found that transgender women showed higher absolute handgrip strength than cisgender women. A separate Women in Sport review concluded there is no direct evidence that hormone suppression fully achieves fairness across all sports. Those gaps matter most at elite levels, where the margin between winning and losing can be a fraction of a second or a single kilogram.

Where the Honest Disagreement Lives

The core dispute is not whether transgender women are cheating. It is whether puberty-driven physical development — bone density, lung capacity, muscle fiber composition — can be fully reversed by estrogen therapy. Research published in a National Institutes of Health journal argues that testosterone-driven changes during male puberty create lasting effects that hormones cannot fully undo. That claim has not been cleanly rebutted by any long-term elite-level study, because that study does not yet exist.

The Cato Institute’s analysis of the fairness debate put it plainly: the real issue is not identity but the competitive advantage that birth sex can confer, and whether hormonal therapy offsets it enough to satisfy a reasonable standard of fair play. That is an honest framing. It moves the argument away from culture-war heat and toward a testable question. The problem is that sports medicine has not yet answered it definitively for elite competition, and courts are being asked to rule before the data is complete.

What Common Sense Says About the Ruling

Women’s sports exist as a protected category precisely because biological sex creates performance differences that matter in competition. That is not a controversial premise — it is the founding logic of Title IX itself. A Court majority affirming that states can protect that category is consistent with the law’s original intent and with basic fairness principles that most Americans across the political spectrum actually share when they think it through.

The counter-evidence on hormone therapy is real and deserves respect. A 52-study meta-analysis is not nothing. But “no measurable difference on average” is not the same as “no advantage at the elite level,” and that distinction matters enormously when a scholarship, a record, or an Olympic spot is on the line. Until science produces longitudinal data on elite transgender athletes over five or more years, policymakers are not wrong to err on the side of protecting the category that Title IX was built to defend.